Search

The cannabis company's special meeting materials and voting instructions might not reach all shareholders before the meeting. < Back Verano Provides Update on Canadian Postal Strike Oct 6, 2025 Cannabis Business Times Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The cannabis company’s special meeting materials and voting instructions may not be delivered to all shareholders’ addresses before the meeting. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Choosing whether to trim cannabis by hand or machine impacts the aesthetic and quality of marijuana buds, as well as operational efficiency. The debate: hand- or machine-trim? is a post from: MJBizDaily. < Back The great cannabis cultivation debate: hand- or machine-trim? May 1, 2025 Margaret Jackson MJ Biz Daily Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Choosing whether to trim cannabis by hand or machine is a decision that impacts both the final aesthetic and the perceived quality of marijuana buds as well as a cultivator’s operational efficiency and the bottom line. The great cannabis cultivation debate: hand- or machine-trim? is a post from: MJBizDaily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

The company has authorized $75 million in cash for the third-quarter closing, reflecting a balanced approach to capital allocation. < Back Village Farms International’s Board Approves $10M Share Repurchase Authorization Sep 29, 2025 Cannabis Business Times Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The authorization reflects the company’s balanced approach to capital allocation, with $75 million in cash for the third-quarter closing. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Ben Carson, who led President Donald Trump’s Department of Housing and Urban Development (HUD) during his first term, is speaking out against a marijuana rescheduling proposal that the current administration is actively considering. < Back Former Trump Cabinet Official Claims Marijuana Rescheduling Would ‘Worsen The Crisis’ Of Crime Sep 4, 2025 Kyle Jaeger Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Ben Carson, who led President Donald Trump’s Department of Housing and Urban Development (HUD) during his first term, is speaking out against a marijuana rescheduling proposal that the current administration is actively considering. In an op-ed published by Fox News on Thursday, the former HUD secretary suggested that reclassifying cannabis as a Schedule III drug under the Controlled Substances Act (CSA) conflicts with the president’s efforts to end “the crime epidemic destroying American cities.” He said while “there are many factors contributing to high crime rates, we cannot ignore one that’s dominated the national debate in recent weeks: the prevalent use of marijuana, a trend which is growing in our urban centers.” “As the president starts cleaning up our streets, a cabal of Soros-funded activists are pushing for a dangerous Blue City-style policy that will worsen the crisis: rescheduling marijuana to Schedule III,” Carson claimed. “Even well-intentioned but misguided activists are now advocating to loosen marijuana restrictions through efforts to reschedule the drug.” A Schedule III designation would not federally legalize cannabis. It would, however, acknowledge that it has medical use and allow state-licensed marijuana businesses to take federal tax deductions they’ve been barred from under an Internal Revenue Service (IRS) code known as 280E. It would also lift certain research barriers that apply to Schedule I drugs. “I urge caution when we consider such sweeping changes. The intent may be compassionate, but the consequences are certainly harmful,” the former Trump administration official wrote. “As someone who’s spent decades caring for the health and well-being of families across America, I have seen firsthand how substance abuse devastates lives and communities.” He also linked cannabis use with increased crime, and he argued that legalization is associated with “substance-use disorders” and “chronic homelessness.” “Negative consequences follow liberalized drug policies like night follows day. It makes sense that order and civil society suffer the more you give license for individuals to engage in antisocial behavior such as abusing drugs,” Carson said. “More and more locations are learning the hard way that easing drug prohibitions can have disastrous consequences.” “If one thing is clear from crime-controlled areas, it’s this: rampant drug use is fueling the fire. This truth is reflected across countless American cities,” he said. “As a former pediatric neurosurgeon who is deeply concerned for America’s future generations, I believe we must approach marijuana policy with caution and allow sound evidence to guide the debate.” “The health, safety and stability of our families depend on thoughtful, responsible leadership—not experimenting with policies that fuel more crime and suffering. Let’s instead focus on what truly makes our towns and cities places where every American can thrive.” The former Cabinet member’s comments come about eight years after he criticized the impact that criminal drug enforcement has on disadvantaged communities. Meanwhile, Trump’s former press secretary Sean Spicer and his long-time advisor Roger Stone recently traded diverging takes on the prospect of the administration moving forward on marijuana rescheduling. Stone separately made the case for reform in an op-ed for Marijuana Moment last week. Nine GOP congressional lawmakers have called on the U.S. attorney general to reject what they called a “corrupt and flawed” marijuana rescheduling proposal. In contrast to that letter from GOP lawmakers, a leading drug policy reform group recently launched a petition urging the president to go further than rescheduling by legalizing marijuana altogether. The post Former Trump Cabinet Official Claims Marijuana Rescheduling Would ‘Worsen The Crisis’ Of Crime appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Virginia’s proposed cannabis legislation attempts to prevent monopolization and promote restorative justice, but the author warns that current operational timelines and fees threaten to undermine these goals by favoring incumbent multi-state operators. The author recommends that Virginia abandon the arbitrary retail launch date and instead implement "Market Readiness" benchmarks, allowing sales to begin only when independent licensees have compliant product available, thus ensuring a competitive market start. < Back Virginia Rejected A Monopoly Model For Marijuana, But Lawmakers Need To Finish The Job (Op-Ed) Dec 10, 2025 Marijuana Moment Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link *“Legislators must ensure the launch mechanics don’t inadvertently hand the keys back to the incumbents before independent operators can even get in the door.”* *By Max Jackson, Cannabis Wise Guys* For years, the story of legal cannabis in America has been a rerun of the same bad movie: corporate lobbyists write the rules, “Big Weed” captures the market and independent farmers are regulated into bankruptcy. Last week, Virginia’s Joint Commission to Oversee the Transition of the Commonwealth into a Retail Cannabis Market decided to change the channel. In October, I warned the Joint Commission in testimony that Virginia faced a choice between two economic models: “Path A,” a limited-license market dominated by incumbent multi-state operators (MSOs), or “Path B,” a competitive market built on independent Virginia businesses. The proposed legislative changes represent a genuine attempt to prevent the monopolization that has plagued legal cannabis markets across the country. The Commission has embraced restorative justice, killed the regulatory barriers that created “cannabis deserts” in other states and built a framework for independent operators to compete. The question is whether the operational timeline will deliver on that promise—or undermine it. *The $10 Million “Penalty” Is Actually A Discount* The proposal requires incumbent pharmaceutical processors to pay a $10 million fee to enter the adult-use market. To the average Virginian, that sounds like a hefty price tag. But let’s be honest about the math—and the history. Virginia’s medical program launched in 2020 as a limited-license, vertically-integrated market. Five pharmaceutical processors—most of them multi-state operators—were awarded exclusive territories with mandatory vertical integration, a structure designed to favor deep-pocketed incumbents over independent operators. Between July and August 2025 alone, that protected medical market recorded nearly $30 million in sales across more than 256,000 transactions. In 2024, The Cannabist Company sold its Eastern Virginia medical operation to Verano Holdings for $90 million. Just last week, The Cannabist sold its Central Virginia operation to Curaleaf for $110 million. Two territories, $200 million in total value. In exchange for this one-time $10 million conversion fee, these companies are being granted licenses that are larger and more powerful than any other tier available to new entrants. They retain their vertical integration—growing, processing and selling their own product—while new businesses are forced to specialize. They already have completed facilities, trained staff, established supply chains and consumer brand recognition. Against proven territory valuations of $90-110 million and a medical market generating $15 million per month, a $10 million conversion fee is not a penalty; it’s a discount on market dominance. *Killing The “Cannabis Desert”* The most significant victory for public safety is the removal of the local referendum option. The failure of the opt-out model is well-documented. In New Jersey, nearly 70 percent of municipalities initially opted out of allowing cannabis businesses, creating vast “cannabis deserts.” This didn’t stop consumption; it simply handed those markets directly to illicit operators who don’t check IDs or test their products. By striking the opt-out provision, the Commission has acknowledged a fundamental truth: you cannot regulate a market if you do not allow it to exist. However, access alone doesn’t guarantee competition. The proposal also establishes a one-mile minimum distance between retail dispensaries, intended to prevent the clustering seen in states like New Jersey, where zoning restrictions force retailers to open across the street from one another. In theory, this promotes geographic distribution. In practice, it transforms retail licensing into a real estate race—whoever secures a location first controls a one-mile radius, and well-capitalized operators with real estate teams will always move faster than independent applicants still assembling financing. Removing the opt-out provision helps by opening more geography to competition, but the mile-radius rule still advantages those who can play the property game at speed. *Restorative Justice Requires Resources* Equally important is the shift in how Virginia defines “impact.” The proposal to include prior felony distribution charges as a qualifier for impact status—rather than a disqualifier—is an absolute victory. It moves beyond performative equity and toward actual restorative justice, acknowledging that the expertise of legacy operators is a feature, not a bug. However, a license is only an opportunity if the resources exist to execute on it. The bill’s commitment to direct 50 percent of the Cannabis Equity Reinvestment Fund into loan capital is a start, but impact licenses are only as helpful as the funding, technical assistance and affordable professional services available to support them. Virginia must ensure these operators can access not just capital, but the legal, accounting and compliance expertise necessary to survive the capital-intensive startup phase—services that incumbents already have in-house. *The 120-Day Trap* As an operational consultant, I must be direct: the timeline in this proposal threatens to undo everything the policy structure is trying to achieve. Here’s the math. Assuming the bill passes early in 2026, the Cannabis Control Authority (CCA) has until July 1 to stand up regulations and process the first round of licenses. Retail sales begin November 1. That gives a newly licensed independent operator exactly 120 days to go from “license in hand” to “product on shelves.” Let me explain what 120 days actually means in cannabis cultivation. A typical flowering cycle runs 60-65 days. Add 3-4 weeks of vegetation before that. Then, 10-14 days for drying and curing. Then testing, packaging and compliance. You’re looking at 100-120 days minimum from clone to compliant, sellable product—assuming everything goes perfectly, your facility is already built, your systems are dialed in and you started cultivation the moment your license arrived. For a new operator still finishing construction, installing equipment, and training staff? The math doesn’t work. They will have nothing to sell on November 1. The pharmaceutical processors, meanwhile, already have inventory. They have flower curing in their vaults right now. They’ll be ready to sell on day one. *Market Readiness, Not Calendar Dates* The solution is straightforward: tie market launch to actual competitive readiness, not arbitrary dates. Virginia should establish “Market Readiness” benchmarks where retail sales begin when a minimum threshold of independent licensees—impact operators, microbusinesses and small cultivators—have received licenses, completed buildout and have product ready for sale. When the independents and the incumbents cross the starting line together, consumers get competition, prices reflect a real market and the policy achieves its stated purpose. This isn’t about delaying the market indefinitely. It’s about aligning the incentives of all market participants so that pharmaceutical processors, independent operators and the state all benefit from a stable, competitive launch. One approach would be to make pharmaceutical processor conversion contingent on independent operator readiness—perhaps even on a regional basis—so that cooperation becomes more profitable than obstruction. When incumbents’ adult-use revenue depends on independents getting operational, the market dynamics shift dramatically. The ready-together framework prevents the first-mover revenue trap that has cemented MSO dominance in state after state. Arizona launched sales roughly 80 days after licensing—but only incumbents with existing inventory could participate, giving them a 6-12 month head start that new operators never recovered from. Virginia has built the right policy framework to avoid that outcome. Now it must build the right launch mechanics. The Commission should amend the current timeline provisions to establish clear market readiness criteria: retail sales commence when the Cannabis Control Authority certifies that licensed independent operators have compliant product available for distribution, ensuring market launch reflects genuine competition rather than incumbent inventory advantage. This preserves the urgency of launching a regulated market while ensuring the Commission’s equity and competition goals aren’t undermined by a calendar date that only pharmaceutical processors can meet. *“Operational” Must Mean Progress, Not Perfection* The proposal includes a 24-month “use it or lose it” rule to prevent license speculation. That’s good policy—if “operational” is defined correctly. In Virginia’s current construction environment, the electrical transformers required for a commercial cannabis facility can face lead times of 12-18 months. Add permitting delays, zoning appeals and on-site construction, and the 24-month window becomes dangerously tight. The standard for retaining a license must be “demonstrable progress”—breaking ground, passing inspections, installing equipment, securing financing—not “open for business.” Without this clarity, the 24-month rule becomes another tool that advantages incumbents with completed facilities while punishing independents for delays entirely outside their control. *Shell Company Scrutiny Needs Speed Limits* The proposal includes provisions requiring the Cannabis Control Authority to scrutinize ownership agreements, management contracts and financing arrangements to prevent MSOs from using shell companies to control nominally “independent” licensees. This is vital—without it, every anti-consolidation provision in the bill becomes meaningless. However, regulatory scrutiny without statutory time limits can be as dangerous as no scrutiny at all. If CCA takes six months to review a management agreement or a financing deal, that delay alone can kill a small business burning through cash while waiting for approval. Virginia must establish clear timelines—30 to 60 days for standard reviews, with defined criteria for what triggers extended review—so that legitimate operators aren’t inadvertently strangled by bureaucratic pace. *Virginia Can Lead—If It Finishes The Blueprint* Virginia has rejected the monopoly model that has failed consumers and small businesses in state after state. The Commission has embraced restorative justice by making felony distribution convictions a qualifier, not a disqualifier. It has eliminated the local opt-out provisions that created “cannabis deserts” in New Jersey and elsewhere. It has built a framework for microbusinesses, shared processing hubs, and impact licensees to compete on a level playing field. But a blueprint is not a building. By establishing clear market readiness criteria that tie launch to competitive preparedness, defining “operational readiness” to protect legitimate businesses from bureaucratic delays and establishing time limits for regulatory review, Virginia can deliver on the promise of a truly competitive market. The Commonwealth has drawn the blueprint for what legal cannabis could look like. Now legislators must ensure the launch mechanics don’t inadvertently hand the keys back to the incumbents before independent operators can even get in the door. *Max Jackson is the founder of Cannabis Wise Guys and specializes in translating between cannabis operations, investment, and public policy. He has provided expert testimony to the Virginia Legislature on preventing market consolidation in emerging cannabis markets.* *Photo courtesy of Max Jackson.* The post Virginia Rejected A Monopoly Model For Marijuana, But Lawmakers Need To Finish The Job (Op-Ed) appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Athletes, Entertainers Urge Trump to Reschedule Marijuana, Offer Clemency, Ease Cannabis Banking < Back Athletes, Entertainers Urge Trump to Reschedule Marijuana... Jun 30, 2025 Mg Magazine Newswire MG Magazine Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link *WASHINGTON —* A high-profile coalition of athletes, entertainers, and advocates has sent a formal letter to President Donald J. Trump urging him to follow through on his public support for marijuana rescheduling and to lead a new era of cannabis reform in America. Led by boxing icon Mike Tyson, NFL Stars Ricky Williams, Jim McMahon, NBA greats Allen Iverson and Kevin Durant, as well as cultural voices like Wyclef Jean, Lil Pump, and Adin Ross, the group is throwing its weight behind Trump’s call to move marijuana to Schedule III—a change they say is “scientifically necessary and politically overdue.” “We fully support your vision for sensible, evidence-based marijuana policies that reflect today’s societal realities and promote safe, regulated access,” the coalition wrote. “Rescheduling marijuana will not only correct outdated federal policy—it will unlock research, innovation, and investment, and bring fairness to businesses and consumers nationwide.” The letter highlights the disparity between federal cannabis laws and the reality in most U.S. states, where the plant is already legal in some form. The group notes that current federal scheduling continues to obstruct medical research, punish legal businesses with excessive taxes, and criminalize behavior that is now broadly accepted. The coalition also urged Trump to pair rescheduling with meaningful clemency action, particularly for nonviolent marijuana offenders still serving outdated sentences, and to advocate for cannabis banking reform to end discriminatory practices harming legal operators. “As a disruptor of the status quo, your leadership on cannabis would be historic,” the letter states. “We are ready to help you push for bold changes that align with the will of the American people and the realities of today’s economy.” This call to action comes at a pivotal moment, as the Biden administration failed to act decisively on marijuana reform despite campaign promises. In contrast, Trump has spoken publicly about marijuana’s medical value, the need for smarter regulation, and the absurdity of continued incarceration for cannabis-related crimes. The coalition includes: Mike Tyson: Boxing Champion, Entrepreneur, & Advocate Wyclef Jean: Grammy-Award Winning Musician & Member of the Fugees Allen Iverson: NBA Superstar Kevin Durant: NBA Champion Ricky Williams: NFL All-Pro & Heisman Trophy Winner Jim McMahon: NFL Pro-Bowler and two-time Super Bowl Champion Kyle Turley: NFL Pro-Bowler; Country Music Artist Adin Ross: Streamer Lil Pump: Rapper; Singer; Songwriter Stephen Jackson: NBA Champion Roy Jones Jr.: Boxing Champion and Hall of Famer Chris Webber: NBA All-Star John “Spider” Salley: NBA Champion; Actor; Sports Commentator Matt Barnes: NBA Champion J.R. Smith: NBA Champion Al Harrington: NBA player, cannabis entrepreneur Dez Bryant: NFL Roland “Champ” Bailey Jr.: NFL Hall of Famer Kyle Turley: NFL Pro-Bowler; Country Music Artist Marvin Washington: NFL Veteran, Super Bowl Champion, Entrepreneur, Reform Advocate Ralo: Hip Hop Recording Artist Boyd Melson: Military Boxing Champion Tony Richardson: Former NFL Player Keith “One Time” Thurman: Boxing Champion < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

LOCAL’d is lending a helping hand to the companies that strengthen the the Washington, DC community through financial and promotional support. Buy a local product, get a free (awesome) gift delivered to you in the District. Help Local'd help local, community businesses! LOCAL'd WEBSITE MENU REVIEWS Delivery# 202-844-2477 *For the fastest service, hit them up on chat! LOCAL’d is lending a helping hand to the companies that strengthen the Washington, DC community through financial and promotional support. Buy a local product, get a free (awesome) gift delivered to you in the District. Help Local'd help local, community businesses! 20% OFF all orders with Promo Code: "Toker20" locald-reviews Recent Reviews Jack The Ripper - LOCAL'd If you're looking for a hazy sativa to keep you going this week take a gander at this local grown Jack The Ripper strain from DC... Toker's Guide Sep 13, 2022 1 min read Sour Diesel - Local'd A long time sativa favorite of mine, Sour Diesel used to be one of the most popular strains in the country in the late 90's and early... Toker's Guide Aug 3, 2022 2 min read MAC 1 - LOCAL'd Here's a really nicely grown, fresh, and mega trich'd out batch of MAC 1 from local-oriented DC recreational (i-71) delivery service... Toker's Guide Jul 7, 2022 1 min read Black Cherry Punch - LOCAL'd There's been a really strong cherry-flavored theme here in the DC cannabis scene recently. We were literally handed three other... Toker's Guide May 20, 2022 1 min read Dirty Squirt - LOCAL'd LOCAL'd not only gifts locally cultivated ganja, they're also the purveyors of 100% local products from local companies. As mentioned in... Toker's Guide Apr 23, 2022 1 min read Agent Orange - LOCAL'd If you'd like to partake in some local grown flower, known for its citrus aroma and flavor, while also contributing more to local DC... Toker's Guide Mar 31, 2022 1 min read Garlic Cookies - LOCAL'd For a local grown, indica-heavy, hard-hitting batch of Garlic Cookies look no further than local-only DC i-71 delivery service, LOCAL'd.... Elle Weeds Feb 24, 2022 1 min read Dessert Runtz - LOCAL'd Dessert Runtz, a mostly indica variety (60/40) by DC i-71 delivery and local business-focused LOCAL'd, is a cross between Cookies & Cream... Maya Francesca Jan 29, 2022 2 min read Black Triangle - LOCAL'd If you're into the idea that buying local and supporting local businesses is of paramount importance right now, like we are, then you... May Jan 14, 2022 1 min read Marionberry Kush - LOCAL'd When LOCAL'd gave me the choice between several varieties to review recently, I didn't hesitate to select Marionberry. I'm into... Toker's Guide Feb 26, 2020 4 min read Lime Skunk - LOCAL'd Happy holidays everyone! I hope you've all been able to toke down on some phenomenal trees over these past couple days! Maybe you even... Toker's Guide Dec 30, 2019 2 min read

CannaCon, a B2B cannabis industry expo, is returning to Washington State, its birthplace, from October 3-4, 2025, at the Clark County Event Center in Vancouver. The event will feature exhibitors, seminars, and networking opportunities for cannabis business professionals, entrepreneurs, investors, and regulators. Angela Grelle, Director of Marketing and Operations, expressed excitement about returning to the Pacific Northwest, a leader in cannabis innovation. < Back CannaCon Returns to Its Home State of Washington, October 3–4, 2025 Sep 10, 2025 Ganjapreneur Ganjapreneur Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link *Vancouver, WA – Sept 8, 2025*– CannaCon, the nation’s premier B2B cannabis industry expo, is proud to announce its highly anticipated return to Washington State, the birthplace of the CannaCon brand. The event will take place October 3–4, 2025, at the Clark County Event Center in Vancouver, Washington. Since 2014, CannaCon has been at the forefront of connecting cannabis business professionals, entrepreneurs, investors, and regulators across the country. After last hosting in Washington in 2019, the expo is making a long-awaited comeback to its home state, bringing with it a robust lineup of exhibitors, industry-leading seminars, and unparalleled networking opportunities. “Washington is where CannaCon began, and returning here feels like coming home,” said Angela Grelle, Director of Marketing and Operations at CannaCon. “The Pacific Northwest has always been a leader in cannabis innovation, and we are excited to provide a platform where businesses from across Washington, Oregon, and beyond can connect, collaborate, and grow.” The two-day event will showcase exhibitors featuring the latest in cultivation technology, dispensary innovations, packaging solutions, financial services, compliance resources, and more. Attendees will also benefit from a diverse seminar schedule featuring expert speakers covering pressing topics such as licensing, compliance, and business strategy. CannaCon Washington promises to be an essential gathering for anyone seeking to succeed in today’s rapidly evolving cannabis market—whether seasoned operator or new entrepreneur. *Event Details:* CannaCon Washington October 3–4, 2025 Clark County Event Center, Vancouver, WA Tickets and exhibitor information: www.CannaCon.org *About CannaCon*CannaCon is the nation’s leading cannabis B2B trade show, hosting events across the United States that bring together industry professionals, entrepreneurs, and investors. With a mission to provide a global marketplace for education, networking, and business development, CannaCon continues to shape the future of the cannabis industry. *Media Contact:*Angela Grelle Director of Marketing and Operations Angela@CannaCon.org < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Stevie Williams, known as "Little Stevie," began his skateboarding career at 12, gaining attention from Element and developing a unique street style. By 18, he ventured into business, securing sponsorships and launching the skate brand DGK. Inspired by cannabis culture, Williams expanded into streetwear and his latest endeavor, Lord Williams Farms, focuses on cannabis lifestyle and technology. He continues to be a pioneer in skateboarding, cannabis, and fashion. < Back Skateboarding Legend Stevie Williams Builds A Cannabis Empire Jun 30, 2025 Clare Sausen Cannabis Now Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Stevie Williams, known initially solely as “Little Stevie,” made his first impression on the skateboarding world more than three decades ago. At 12, he ripped through Philadelphia’s famous LOVE Park and catching the attention of the legacy skate brand Element then appearing in their Fine Artists Vol 1 Collection in 1994. With skills far beyond his age, he soon became synonymous with the city, developing a raw street style that reverberated to the East Coast skating scene at large. By 18, Williams had extended his acumen to the business sphere. His career and sponsorship opportunities grew in succession with global names including G-Shock, Reebok and Playboy for exclusive collabs and signature product lines. With an entrepreneurial spirit that had yet to be satiated, Williams, with friend and collaborator Eli Soto, launched the skate brand DGK (Dirty Ghetto Kids)—a reclamation of the stereotype Williams says he faced growing up Black in the inner city—cementing his legacy on the board and beyond. Pursuing an interest in fashion with inspiration rooted in cannabis culture, Williams is now as well-known for streetwear as he is for skating. DGK currently features a litany of goods directly inspired by the plant, from a Team Indica line of basketball wear to rolling trays adorned with works of art. “DGK represents urban culture, so we support the cannabis space and the movement by representing that culture correctly,” Williams says. His latest endeavor, Lord Williams Farms, is inspired by the energy of downtown Los Angeles, utilizing NFC chip technology popular in the city’s legal weed industry. “Lord Willaims is a journey brand in the cannabis lifestyle space,” he says. “It’s a blend of technology, lifestyle, cannabis and psychedelics.” While it’s typically applied in cannabis for product verification, digital collectibles and cryptocurrency transactions, Williams uses it to engage his consumers to point-and-shoot their tag toward a product experience aligned with his vision far beyond the limitations of a static graphic. Through ventures ranging from skate gear to streetwear with the application of innovative platforms, Williams continues to solidify his legacy as a multifaceted pioneer in skateboarding, cannabis and fashion. The post Skateboarding Legend Stevie Williams Builds A Cannabis Empire appeared first on Cannabis Now. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

An industry organization is calling for the enforcement of Texas Gov. Greg Abbott’s executive order on regulating cannabinoid hemp products. < Back Texas Hemp Business Council Supports Protections for Minors Sep 11, 2025 Cannabis Business Times Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The industry organization is urging the practical enforcement of Texas Gov. Greg Abbott’s executive order on regulating cannabinoid hemp products. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

The Maine Office of Cannabis Policy issued a mandatory recall for Yani “Watermelon Chimera” adult-use live resin vape cartridges, batch number 1A40D0300006145000011115, produced by NorCO Outdoor Cannabis. The recall was prompted by a consumer complaint and subsequent testing, which found unsafe levels of the insecticide Chlorfenapyr, toxic to humans. The recalled products were sold between July 10, 2025, and October 16, 2025, and consumers are advised to dispose of or return them. < Back Maine Regulators Recall Batch of Cannabis Vape Cartridges Citing Dangerous Pesticide Oct 29, 2025 Graham Abbott Ganjapreneur Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The Maine Office of Cannabis Policy (OCP) on Monday issued a mandatory recall for a batch of adult-use live resin vape cartridges after testing revealed unsafe levels of Chlorfenapyr, an insecticide known to be toxic to humans. The recall affects Yani “Watermelon Chimera” cartridges produced by NorCO Outdoor Cannabis under the batch number 1A40D0300006145000011115. The products were sold as 0.5-gram and 1-gram live resin vape cartridges at 21 licensed dispensaries throughout the state, and the products were in circulation between July 10, 2025, and October 16, 2025. [image: Recalled Yani-brand vape cartridge packaging. Photo credit: Maine Office of Cannabis Policy (OCP)] OCP ordered the recall following a consumer complaint about an adverse health reaction that prompted an official investigation, which included testing the offending batch of products. “The products are being recalled due to those testing results showing unsafe levels of the pesticide Chlorfenapyr. Inhaling cannabis containing unsafe levels of Chlorfenapyr can lead to high fever, sweating, nausea, vomiting, and/or altered mental status.” — OCP statement Officials recommended consumers check the packaging of their cannabis vape products for the affected batch number, and safely dispose of any recalled products or return them to the retailer where they were purchased. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Wisconsin senators debated a newly filed Republican-led bill to legalize medical marijuana, with the Senate Health Committee chair indicating the proposal would advance quickly. The bill, introduced by Senate President Mary Felzkowski and Sen. Patrick Testin, was supported by patient testimony and advocates who emphasized the need for alternative medicine. Key provisions of the bill include a list of qualifying conditions (such as cancer, PTSD, and severe chronic pain), allowable forms of cannabis (excluding smokeable forms), a two-year patient/caregiver registration with a $20 annual fee, and regulated dispensaries requiring pharmacists. The legislation does not allow home cultivation and permits employers to fire or refuse to hire workers based on medical marijuana use, though it establishes parental rights and housing protections. Despite support, the Republican Assembly speaker suggested the bill is "unlikely" to pass his chamber due to its broad scope. Democrats, including Gov. Tony Evers, support legalization, and a recent poll shows 67% of Wisconsin voters favor the policy change. < Back Wisconsin Senators Hold Hearing On GOP Leader’s New Medical Marijuana Legalization Bill, With Plan To Vote On It ‘Fairly Quickly’ Oct 22, 2025 Kyle Jaeger Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Wisconsin senators on Wednesday took up a newly filed Republican-led bill that would legalize medical marijuana in the state. Just one week after Senate President Mary Felzkowski (R) and Sen. Patrick Testin (R) filed the legislation, the Senate Health Committee debated the proposal at a hearing, taking testimony from patients and other advocates. Members did not vote on the bill, but the chair said the panel would be advancing it “fairly quickly,” potentially at its next meeting in November. An Assembly companion version was also filed by Assemblymember Patrick Snyder (R) and lawmakers, but it has not yet advanced in their chamber. “Illness does not discriminate. It affects people from all walks of life. There is no doubt that each and every one of us knows someone that has suffered through an illness and struggled to find ways to make it through each day,” Testin said at the hearing, describing how his grandfather used medical cannabis to treat cancer symptoms decades ago. “While there are often medications that doctors can prescribe to help combat these illnesses, many come with side effects that can make living a normal life much more difficult.” “In some cases, the only option for pain relief is to take opioids on a long-term basis, which can lead to a whole host of other challenges that already afflict our state and our residents,” he said. “However, there is an alternative.” “Both red and blue states alike have been able to come together and recognize that this is a viable option for patients within their respective states, regardless of the partisan makeup of that that state,” the senator said. “Medicine is never a one-size-fits-all, and it’s time for Wisconsin to join the majority of the country and add another option, which may help patients find relief they need.” Felzkowski shared her story of overcoming breast cancer, struggling with the side effects of opioids and other prescription medicines she was prescribed and then asking her oncologist what they thought about the idea of legalizing medical cannabis. The doctor told her that while marijuana is not a miracle cure, it’s another tool in the toolbox that could benefit many patients. “Wisconsin is on an island surrounded by neighboring states that allow the use of medical cannabis products. These products are not for everyone—but for others that use opioids or other medications to treat their health condition, the side effects of these drugs can be debilitating,” the Senate president said. “Someone who suffers from a serious health condition should not have to make the choice to travel to another state or break the law so that they can try an alternative medicine for relief. Unfortunately, this is a position in which we put many Wisconsinites.” Sen. Rachael Cabral-Guevara (R), chair of the Health Committee, said that, as a healthcare provider herself, she’s heard stories about the medical potential of cannabis “all the time.” And while some providers might not want to participate in a medical marijuana program, “there are many that do…because we know our patients are going and purchasing these products to manage their symptoms from other states.” “I will also say, as someone that does prescribe medications, I would rather my patients be upfront and truthful on what products they’re using to manage their symptoms, than having to guess,” she said. “There are a lot of people that will not come out and be straightforward because they’re afraid of consequences, and I hope that this bill would eliminate that fear that people are using for medicinal purposes to manage their conditions, so that individuals who are prescribing can take that into consideration when thinking of dosing and contraindications.” Pressed on the lack of employment protections for would-be medical marijuana patients in her legislation, Felzkowski said “everything that’s done in this bill is to hopefully to get it to pass through both houses.” “I always say if I was queen for a day, I’d probably write a whole bunch of legislation differently,” she said. “But we have to make sure that everybody in our caucuses are comfortable with legislation.” One witness who testified was Norah Lowe, a 17-year-old with a rare neurodevelopment condition known as Rett syndrome, who spoke to members through computer audio given her associated speech impairment. “My friends with Rett syndrome who use medical cannabis actually sleep through the night and see extensive relief from painful muscle spasms. Why can’t I get relief from mine?” she asked. “My friends who have access to cannabis see profound improvements in their therapies and communication skills. Why can’t I experience the same types of advancement of skills?” She was accompanied by her mother, Megan Lowe, who also spoke to the benefits of medical marijuana that she experienced while going through treatment for breast cancer. “I used it to find relief from my hot flashes, my insomnia, my crippling anxiety, my neuropathy, my restless legs, my itchy skin—the list goes on,” she said. “Cannabis made my cancer treatments and recovery bearable so that I could go back and returning to caregiving for her.” Wisconsin’s GOP Assembly speaker said earlier this month that he hopes lawmakers in the state can “find a consensus” on legislation to legalize medical marijuana. But he added that the new cannabis bill filed by his Republican leadership counterpart in the Senate is “unlikely” to pass his chamber because it is “way too broad and way too wide-ranging.” As the 2025 session was set to get underway, Felzkowski said she was “hoping to have a conversation” in the legislature about legalizing medical marijuana this year—though the Republican Assembly speaker still represented “an obstacle,” she added. The Senate leader has previously sponsored medical cannabis legislation in past sessions, formally introduced the new legislation. *Here are the key provisions of the Senate president’s latest medical marijuana bill.* - Qualifying conditions for patients would include cancer, HIV/AIDS, post-traumatic stress disorder, seizures or epilepsy, glaucoma, severe chronic pain, severe muscle spasms, severe chronic nausea, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, inflammatory bowel disease, chronic motor or vocal tic disorder, Tourette syndrome and any terminal illness with a probable life expectancy of less than one year. - Allowable forms of medical cannabis products would include concentrates, oils, tinctures, edibles, pills, topical forms, gels, creams, vapors, patches, liquids and forms administered by a nebulizer. Cannabis in a form that could be smoked would not be allowed. - Home cultivation would not be allowed. - Patients could designate up to three caregivers who could purchase and possess medical cannabis products on the their behalf. - Patient and caregiver registrations would last for two years and could then be renewed. The annual fee would be $20, and people could have their registrations rescinded for being convicted of a felony or for violating certain drug law. - Dispensaries would be required to employ pharmacists who would need to consult with patients or caregivers and recommend a daily dosage. A patient getting medical marijuana for the first time could get up to a 30-day supply and on subsequent visits could receive up to a 90-day supply. - Patients’ use of medical cannabis would need to be recorded in the state’s Prescription Drug Monitoring Program. - The bill would establish parental rights and housing discrimination protections for medical cannabis patients and caregivers, but it would allow employers to fire or refuse to hire workers based on their use of medical marijuana. - Patients and caregivers could only possess medical cannabis at their own residences or when traveling between dispensaries and their homes. There would be a $25 civil penalty for failing to carry a registry ID card when possessing medical marijuana or for possessing cannabis at locations other than those specified as being allowed. - Medical cannabis products would be exempt from sales taxes. - The state would license cultivation, processing, laboratory and dispensary businesses, subject to certain residency and eligibility requirements and annual fees and penalties for violations. - A new Office of Medical Cannabis Regulation would be established under the Department of Health Services to oversee the patient and caregiver registry and dispensaries. Its director would be appointed by the governor. - The Department of Agriculture, Trade and Consumer Protection would oversee and regulate cannabis cultivation, processing and testing. - Localities would not be able to regulate medical cannabis businesses or restrict their zoning. Meanwhile, a Republican candidate for governor of Wisconsin said in July that he was “open to considering different opportunities” when it comes to legalizing medical or adult-use marijuana in the state, though he has provided little in the way of specifics so far. On the Democratic side, current Gov. Tony Evers (D), who supports legalizing cannabis, will not be seeking re-election. But he said in June that if his party can take control of the legislature, the state can “finally” legalize marijuana so that residents don’t have to go to neighboring Illinois to visit its adult-use market. Separately in June, a poll from Marquette Law School found that two in three Wisconsin voters support legalizing marijuana. The survey found that support for cannabis reform has generally increased over time since the institution first started tracking public opinion on legalization in 2013, with 67 percent of voters now backing the policy change. That’s 17 percentage points higher than the 2013 results. Democrats are the most likely to favor legalizing cannabis, at 88 percent, followed by independents (79 percent). However, a majority of Republicans (56 percent) said they’re still opposed to adult-use legalization. Underscoring the importance of party control, the state’s Republican-controlled Senate and Assembly this summer rejected another attempt to legalize marijuana, defeating amendments to budget legislation that would have ended prohibition in the state and established new medical and recreational cannabis programs. Evers has routinely attempted to change that policy as part of his budget requests—and Democratic leaders have similarly pushed for reform. Republicans in the legislature also cut the marijuana provisions from a state budget proposal in May, as they’ve done in past sessions. Despite Republicans’ move to cut legalization from the budget legislation, party leaders recently acknowledged that the debate over medical marijuana legalization is “not going to go away,” and there’s hope it can be resolved this session. *— Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.* *Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. —* “I don’t think anyone is naive enough to think that marijuana and THC products aren’t present in the state of Wisconsin when they are readily available over state lines, so I think we need to come to an answer on this,” Assembly Majority Leader Rep. Tyler August (R) said in February. “I’m hopeful that we can.” “If we’re going to call it medical marijuana, it needs to be treated like a pharmaceutical. But the marijuana debate is going to be something that is not going to go away,” Sen. Dan Feyen (R), the assistant majority leader, said at the time. “The margins are tighter.” There have been repeated attempts to legalize medical marijuana in the legislature over recent years, including the introduction of legislation from Assembly Speaker Robin Vos (R) that called for a limited program facilitated through state-run dispensaries. That proved controversial among his Republican colleagues, however, and it ultimately stalled out last year. Evers previewed his plan to include marijuana legalization in his budget in January, while also arguing that residents of the state should be allowed to propose new laws by putting binding questions on the ballot—citing the fact that issues such as cannabis reform enjoy sizable bipartisan support while the GOP-controlled legislature has repeatedly refused to act. Previously, in 2022, the governor signed an executive order to convene a special legislative session with the specific goal of giving people the right to put citizen initiatives on the ballot, raising hopes among advocates that cannabis legalization could eventually be decided by voters. The GOP legislature did not adopt the proposal, however. Evers said in December that marijuana reform is one of several key priorities the state should pursue in the 2025 session, as lawmakers work with a budget surplus. Days after he made the remarks, a survey found the reform would be welcomed by voters in rural parts of the state. Nearly two thirds (65 percent) said they support legalizing cannabis. Last May, the governor said he was “hopeful” that the November 2024 election would lead to Democratic control of the legislature, in part because he argued it would position the state to finally legalize cannabis. “We’ve been working hard over the last five years, several budgets, to make that happen,” he said at the time. “I know we’re surrounded by states with recreational marijuana, and we’re going to continue to do it.” A Wisconsin Democratic Assemblymember tried to force a vote on a medical cannabis compromise proposal last year, as an amendment to an unrelated kratom bill, but he told Marijuana Moment he suspects leadership intentionally pulled that legislation from the agenda at the last minute to avoid a showdown on the issue. Meanwhile, the state Department of Revenue released a fiscal estimate of the economic impact of a legalization bill from then-Sen. Melissa Agard (D) in 2023, projecting that the reform would generate nearly $170 million annually in tax revenue. A legislative analysis requested by lawmakers estimated that Wisconsin residents spent more than $121 million on cannabis in Illinois alone in 2022, contributing $36 million in tax revenue to the neighboring state. Evers and other Democrats have since at least last January insisted that they would be willing to enact a modest medical marijuana program, even if they’d prefer more comprehensive reform. *Photo courtesy of Philip Steffan.* The post Wisconsin Senators Hold Hearing On GOP Leader’s New Medical Marijuana Legalization Bill, With Plan To Vote On It ‘Fairly Quickly’ appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5